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ABST RACT

The progress made over the past years in the field of cancer therapy
has led to a significant decrease in cancer mortality, but these
therapies have many adverse effects, cardiovascular effects being
among the most frequent ones. For increasing lifelong expectancy of
surviving cancer patients, cardiac monitoring represents an
important task. Current studies and practice recommend
echocardiography using strain analysis for monitoring the cardio
toxic effects of cancer therapy. The potential of combining imaging
techniques with biomarkers for the early detection and diagnosis
seems a promising path for future research.

Introduction
The progress made over the past years in the field of
cancer therapy has led to a significant decrease in cancer
mortality. However, these therapies have many adverse
effects, cardiovascular effects being among the most
frequent ones. In addition to the fact that they decrease the
quality of life, they can lead to a reduction in the overall
survival rate, independently of the prognosis of cancer
disease [1]. In fact, the term cardiotoxicity refers to
myocardial dysfunction and heart failure (HF), the most
redoubtable complications of these therapies, which occur
in variable proportions, being estimated at 1.7-20.1% for
trastuzumab and 1.6-4% for bevacizumab [2].
Currently, efforts are aimed at the early detection of left
ventricular dysfunction (LVD) for the initiation of prompt
treatment, without compromising cancer therapy. Many
studies investigate the role of biomarkers in the early
detection of LVD, before this becomes severe enough to
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induce a decrease in the left ventricular ejection fraction
(LVEF). Among the most studied markers, there are
cardiac troponins and natriuretic peptides [3].

Discussions
Troponins
Troponins represent a complex formed by 3 subunits:
troponin T (cTnT), troponin I (cTnI), and troponin C
(cTnC). Isoforms T and I have cardiac specificity, while
cTnC is present in the myocardium as well as in striated
muscles [4,5]. Most frequently, their measurement is
performed in case of acute coronary syndrome, being
essential for the diagnosis and guidance of the therapeutic
approach [6]. However, any myocardial lesion, regardless
of its mechanism of occurrence, which induces myocyte
membrane damage, also induces intracellular depletion of
troponins and its subsequent release into the blood [7-11].
Drugs that induce progressive/chronic myocardial injury
cause a small but persistent increase in troponins, which is
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directly proportional to the duration of the therapy [12-16].
Many studies investigate their utility in LVD screening in
cancer patients. For this review, 16 studies have been
analyzed. Their characteristics and the main results
obtained are summarized below (Table 1) [17-22].
All studies included samples of patients with HERpositive breast carcinoma. One study [7] included patients
who did not receive anthracycline prior to trastuzumab
therapy.

Regarding the patients sequentially treated with
anthracyclines and trastuzumab, studies report divergent
results. Some authors consider that increased or detectable
troponin values observed during the treatment with
trastuzumab might be the result of anthracycline toxicity
because they occur shortly after the initiation of
trastuzumab therapy and subsequently tend to normalize
[8,11,12,21]. A possible explanation could be the different
cardiotoxicity mechanisms of the two groups of drugs [23].

Table 1. The characteristics and the main results of the studies investigating cardiac troponin modifications in
HER2+ breast cancer patients treated with trastuzumab
Study (year)

Troponin
type

Troponin measurement

Main results

Ponde N et al. (2018) [7]

cTnT1

Baseline, 2 wks2
18 wks

2.9% elevation at 18 wks

Zardavas et al. (2017) [8]

us-cTnI3
hs-cTnT4

Baseline, 13,25,52 weeks
18,24,30 mo

No significant increase; high troponin levels
at baseline are predictive of LVEF drop5

Goel S et al. (2011) [9]

cTnI

Before and 24h after

No troponin elevation

Baseline
3,6 mo7

High hs-cTnI levels at 3 mo predictive of
cardiotoxicity at 6 mo

6

Sawaya H et al. (2011)
[10]

hs-cTnI

Sawaya H et al. (2012)
[11]

us-cTnI

Baseline, every 3 mo
during treatment

Elevated usTnI concentrations at 3 mo are
predictive of subsequent cardiotoxicity

Ky B et al. (2014) [12]

cTnI

Baseline 3,6 mo

Values at 3 mo predictive of cardiotoxicity
(HR=1.36; p=0.012)
Changes in TnI values from baseline
compared to 3 mo are predictive of
cardiotoxicity (HR8=1.38; p=0.02)

Fallah-Rad et al. (2011)
[13]

cTnT

Baseline
3,6,9,12 mo

No increases over time

Putt M. et al. (2015) [14]

hs-cTnI

Baseline
3,6,9,12,15 mo

Maximum hs-cTnI values at 6 mo (12x
baseline value)
Not predictive for concurrent (p=0.30) or
subsequent cardiotoxicity (p=0.14)

Kitayama H et al. (2017)
[15]

hs-cTnT

Baseline
Every 3 to 6 mo

Patients with cardiotoxicity had elevated hscTnT values
Stable troponin values in patients without
cardiotoxicity

Katsurada K
et al. (2014) [16]

hs-cTnT
hs-cTnI

Baseline
3,6,9,12,15 mo

Maximum hs-cTnT levels at 3 and 6 mo
hs-cTnT changes at 6 mo correlate with
LVEF drop at 15 mo (r = -0.56, p < 0.05)

Mokuyasu S et al. (2015)
[17]

hs-cTnI

Onitilo AA et al. (2012)
[18]

cTnI

Baseline; every 3 wks up
to 1 year

No elevations

Morris PG et al. (2015)
[19]

cTnI

Every 2 wks during ChT
and then at 6,9,18 mo

Detectable cTnI at 2 weeks after
anthracycline
Detectable cTnI before maximum LVEF
drop but not an independent predictive factor

8.9% of anthracycline treated patients and
3% of trastuzumab treated patients had hscTnI elevations
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de Vries Schultink AHM
et al. (2018) [20]

hs-cTnT

Baseline
3,12,24,36,52,64,78,92
wks

Maximum values of hs-cTnT at 3 wks after
anthracycline treatment

Cardinale D et al. (2010)
[21]

cTnI

Every 1-3 wks

cTnI strongest independent predictive factor
for cardiotoxicity (HR=17.6; p=0.001)
patients with high cTnI who develop HF9 are
less likely to recover despite the treatment
(HR=2.88; p<0.001)

Dhir V et al. (2019) [22]

hs-TnI

Before trastuzumab

No correlations between with LVEF drop

cTnT1 – troponin T; wks2 - weeks; us -cTnI3 – ultra-sensitive troponin I; hs-cTnT4 – high-sensitive troponin T;
LVEF5 - ; hs-cTnI6 – high-sensitive troponin I; mo7 - months; HR8 – hazard ratio; HF9 – heart failure
For example, Mokuyasu et al. [17] compared cTnI
values in patients treated with anthracyclines and patients
treated with trastuzumab. The results show that 8.9% of the
patients who were also treated with anthracyclines had an
increase in cTnI values compared to 3% of the patients
treated with trastuzumab. The patients who received no
anthracyclines did not have increased hs-cTnI values.
Zardavas et al. [8] demonstrated that in patients with
high cTn values, these were already present before the
initiation of the therapy with trastuzumab and did not
increase significantly afterwards, and that these patients
had a 2.4-4.5 times higher risk of a decrease in LVEF.
Similarly, Sawaya et al. [11] showed that the highest uscTnI values were recorded shortly after the completion of
the treatment with anthracyclines, followed by their
decrease during trastuzumab therapy. According to this
study, us-cTnI measurement after the completion of
anthracycline treatment has a sensitivity of 48% and a
specificity of 73% as a predictor of subsequent
cardiotoxicity. The usefulness of troponins I as a
prognostic marker of cardiac dysfunction was also
demonstrated in the study conducted by Ky B et al. [12].
The study carried out by Cardinale et al. [21] also
reported increased troponin values in the majority of the
patients (23 of the 36 patients with increased values) at the
beginning of the treatment with trastuzumab, with their
normalization over the following 3 months. In addition, the
authors showed that cTnI values represent the strongest
independent predictor of cardiotoxicity. Furthermore, the
authors indicated that patients with high troponin levels
who develop cardiotoxicity have lower chances of LVEF
recovery compared to patients with normal cTnI values
(36% vs. 100%) under optimal medical treatment.
The study performed by Katsurada K et al. [16] showed
that hs-cTnT values at 6 months represent a predictive
factor of the 10% LVEF reduction at 15 months, suggesting
that this would be a more useful marker than hs-cTnI. A
more recent study [20, 23] also demonstrated the predictive
value of hs-cTnT at 3 weeks after the treatment with
anthracyclines regarding the trastuzumab-induced
decrease in LVEF.
36

In some studies, [14,19], despite an increase in the
troponin values recorded during treatment, the authors
could not demonstrate their predictive value in the early
detection of cardiotoxicity. On the other hand, there are
studies in which the increase in troponins during therapy
was not demonstrated [9,13,18,22].
The only study comprising patients treated exclusively
with trastuzumab [7] suggests that high troponin values
occur in a small number of patients and their measurement
is not useful for monitoring trastuzumab-induced
cardiotoxicity, but it should be taken into consideration that
the small sample and the reduced number of cardiac events
did not allow statistical analysis.
In conclusion, although there are many studies that
show the usefulness of troponin measurement for the early
detection of cardiac toxicity or for the identification of
patients at risk of developing HF during the therapy with
trastuzumab after anthracycline treatment, further studies
with larger samples and standardized measurement
methods are required for the implementation of this method
in clinical practice. Comparing the results is difficult since
different cut-off values for troponin as a marker of
cardiotoxicity have been chosen. Moreover, troponin
measurement presents a high variability because of the
different assays that are used. The imprecision of a typical
troponin assay that was used in the past was between 1020% at the 99th percentile. The new hs-assays managed to
lower this imprecision below 10% [24].
Brain Natriuretic Peptide
The family of natriuretic peptides includes the atrial
natriuretic peptide, brain natriuretic peptide (BNP), and Ctype natriuretic peptide (a peptide secreted by the vascular
endothelium). BNP is released mainly by atrial myocytes
under normal conditions, and by ventricular myocytes in
the presence of congestive HF. Thus, increased BNP values
are the hallmark of ventricular dysfunction. The precursor
pre-proBNP is cleaved into the biologically active BNP
molecule and the inactive N-terminal proBNP (NTproBNP) fragment. In patients with HF, BNP is more
increased than the atrial natriuretic peptide and has a half
higher half-life (20 min vs. 2 min), while NT-proBNP has
the highest half-life (approximately 120 min) and thus
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persists more in circulation [25]. BNP values are under the
influence of several factors. Higher BNP values are seen in
older patients (the cut-off point for HF jumps from 450 to
900 pg/ml in patients over 50 years) and in females, but
obesity leads to significantly lower BNP. Cut-off points for
diagnosing HF need to be higher if the estimated
glomerular filtration rate is lower than 60 mL/min/1.73 m2
[25,26].
The widespread use of BNP in clinical practice has led
to its study in various chemotherapy regimens. In
anthracycline-based therapy, LVD, symptomatic HF, or
acute coronary syndrome were associated with BNP values
above 100 pg/mL. NT-proBNP elevations correlate with

diastolic and systolic dysfunction after high dose
chemotherapy [27,28].
So far, studies have not shown a useful role for
BNP/NT-proBNP monitoring during trastuzumab
treatment. This might be explained by the low
cardiotoxicity of trastuzumab compared to anthracyclines
and the difference in assays and cut-off values used in
various studies [28]. Table 2 provides a summary of the
results [8-11,13,14,18,20,29-34]. Studies have not looked
specifically for the influence of bevacizumab therapy on
BNP in breast cancer patients. Two to four percent of the
subjects on bevacizumab treatment develop LVD that
associates increased BNP levels [35].

Table 2. NT-proBNP1/BNP2 changes during the trastuzumab treatment
Study (year)

NT-proBNP/BNP measurement

Main results

Zardavas et al.
(2016) [8]

baseline; wks3
18,24,30,36

Elevated NT-proBNP does not predict a significant
LVEF5 drop

Goel et
(2011) [9]

baseline, after 24 hours

No significant change in NT-proBNP

Sawaya et al.
(2011) [10]

baseline, 3 and 6 mo

Changes in NT-proBNP do not predict cardiac
toxicity

Sawaya et al.
(2012) [11]

baseline; 3,6,9,12,15 mo

No association between NT-proBNP and cardiac
toxicity

Fallah-Rad et
al. (2011) [13]

before
anthracycline
and
trastuzumab; 3 wks after the final
cycle; 12 mo after trastuzumab

No difference between the patients who developed
cardiomyopathy and those who did not

Putt
et
al.
(2015) [14]

baseline; 3,6,9,12,15 mo

No significant increase in NT-proBNP

Onitilo et al.
(2012) [18]

baseline; every 3 wks up to a year

No difference in NT-proBNP associated with a
LVEF3 drop

de
Vries
Schultink et al.
(2018) [20]

before anthracycline, baseline
before trastuzumab, up to 92 wks
after trastuzumab

Prior treatment with anthracyclines followed by
trastuzumab does not elevate NT-proBNP

Advani et al.
(2017) [29]

at baseline, days 1,2,3, and 7 during
1st and 2nd cycle

Transient increase in NT-proBNP in the first two
days of the second cycle

Yu et al. (2016)
[30]

baseline 6,12,18,24 and 30 wks

No significant increase in BNP

El-Sherbeny et
al. (2019) [31]

baseline 3,6,9 and 12 mo

No significant increase in NT-proBNP

Şendur et al.
(2015) [32]

at 9 and 52 wks

No difference in NT-proBNP after the treatment;
cardiac toxicity associated higher NT-proBNP

Matos et al.
(2016) [33]

baseline, after 4,8,12 mo during
trastuzumab

No significant difference between patients with and
without a LVEF drop

Grover et al.
(2013) [34]

baseline and 4 mo

No difference in NT-proBNP after anthracyclines or
trastuzumab

al.

13,25,52;

mo4

NT-proBNP1 - N-terminal pro-hormone brain natriuretic peptide; BNP2 - brain natriuretic peptide; wks3 – weeks;
mo4 – months; LVEF5 – left ventricular ejection fraction
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Galectin-3
Galectins are β-galactoside-binding lectins with at least
one carbohydrate recognition domain. There are 15 types
of galectins, distinguished from one another by the type of
carbohydrate recognition domain. Galectin-3 is involved in
numerous cellular processes such as cellular
differentiation, inflammation, fibrosis, and angiogenesis.
Cardiovascular diseases such as HF, ischemic heart
disease, atrial fibrillation, and renal dysfunction are
associated with increased serum galectin-3 values. At the
same time, breast tumor tissue has an increased expression
of galectin-3, and triple negative breast cancer expresses
more galectin-3 than other types of breast cancer [36].
Patients with breast cancer have higher serum galectin3 levels compared to healthy subjects (18.41 ng/mL in
cancer patients and 6.73 ng/mL in controls (p<0.0001).
After 3 and 6 months of trastuzumab, anthracycline and
taxane treatment, galectin-3 levels were increased
compared to baseline. At the same time, HER2- patients
had higher galectin-3 values than HER2+ patients [37]. In
contrast, in another study, galectin-3 levels did not increase
from baseline after 15 months of trastuzumab, doxorubicin,
and paclitaxel treatment [14].
Echocardiographic markers of cardiac dysfunction
Advances in cancer treatment over the last decades
have remarkably improved the survival rates of patients
diagnosed with solid and hematologic malignancies.
Unfortunately, several chemotherapeutic agents (e.g.,
trastuzumab, bevacizumab) are known to have cardio toxic
effects [37]. Ventricular dysfunction and heart failure, as a
complication of cancer therapy, have become major public
health concerns, as they are associated with poor prognosis
and long-term morbidity and mortality [38]. The
development of a subclinical left ventricular dysfunction
(cancer therapy–related cardiac dysfunction [CTRCD]),
defined by a threshold change in LV ejection fraction
(LVEF), may be seen in up to 42% of the patients with
cancer in selected treatment groups [39].
Therefore, the early diagnosis and control of cancer
therapy-related cardiac dysfunction CTRCD is of crucial
importance in patients undergoing therapies. In the absence
of robust risk prediction models, cardiologists are very
interested in the use of more sensitive markers to detect
early myocardial dysfunction [40], for CTRCD prevention.
The most frequent echocardiographic markers used in
cancer patients are as follows: LVEF by 2D TTE; VTI:
lateral S wave in both LV and RV; DTI: the detection of
strain (GLS versus GCS versus GRS) and free wall RV
strain.
One of the conventional methods for monitoring
cardiac function in patients receiving cancer therapy is the
determination of 2D left ventricular ejection fraction
(LVEF) with serial transthoracic echocardiography (TTE).
A value <53% of LVEF or a decrease >10% in LVEF
38

during cancer treatment is consistent with cardiac systolic
dysfunction [41].
However, this strategy fails to detect early subtle
alterations in LV systolic function, as LVEF is dependent
on hemodynamic conditions. Tissue velocity imaging
(TVI) and strain imaging are novel, sensitive, non-invasive
echocardiographic techniques that allow the early
detection of LV systolic dysfunction, before a decrease in
conventional LVEF [42]. Tissue velocity imaging has been
validated in murine models of chemotherapy-induced
cardiac dysfunction [43] and more recently, evaluated in
the clinical setting of trastuzumab-induced cardiac
dysfunction [13]. Neilan et al. demonstrated that a decrease
in LVEF, detected by conventional echocardiographic
measures (2D LVEF), was observed on day 5 in mice
treated with chemotherapy, whereas DTI indices, such as S
wave maximal velocity, dropped significantly earlier, on
day 2. These findings were corroborated by Jassal et al.
[44] in a study conducted in 2009, in which DTI parameters
decreased within 24 hours in mice treated with doxorubicin
plus trastuzumab, while a decreased LVEF was observed
only on day 4.
In the echocardiographic assessment of both left and
right ventricular inotropy, tissue Doppler measures, such
as S or E wave maximal velocities, can be used to quantify
regional systolic and diastolic function with greater
accuracy than conventional measures such as LVEF or RV
FAC [45]. However, we should acknowledge that systolic
velocities, being Doppler derived measures, are angledependent. Thus, a good alignment of the Doppler
interrogation line with the region of interest is mandatory
in order to obtain the correct peak velocities. Nonetheless,
peak systolic tissue Doppler velocities can be affected by
the overall motion of the heart and the afterload pressures,
particularly in the RV [46]. Several investigators have
demonstrated an early reduction in lateral E velocity of the
mitral annulus in patients receiving anthracyclines [47] but
not trastuzumab, which remained reduced during the
treatment and for several years thereafter. In a study by
Negishi et al., [48] a 10% reduction in E velocity was
observed in patients who developed CTRCD.
Nevertheless, the reduction was neither statistically
significant nor predictive of subsequent reduction in
LVEF. In a recent study concerning the RV dysfunction,
Keramida et al. [49] showed a global and uniform effect of
trastuzumab on myocardial function, affecting both the left
and right ventricles. The RV dysfunction was
demonstrated by a decrease in both TAPSE and S wave,
criteria of an abnormal longitudinal function. Both
techniques (M-mode echography and Doppler tissue
imaging) are angle-dependent, but also load-dependent.
Among the measures of myocardial function,
echocardiography-measured
peak
systolic
global
longitudinal strain (GLS) is the most extensively studied
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marker and it provides an easy, inexpensive, and
quantitative assessment of the global long-axis systolic
function [50]. As a general idea, strain is defined as a
percentage change in myocardial deformation and strain
rate as the speed of deformation of myocardial segments.
Neither the strain nor the strain rate derived parameters
represent pure myocardial contractility, and none of them
is load-independent [51,52]. Several studies have linked
threshold changes in GLS or an absolute GLS value during
cancer treatment with the subsequent development of
CTRCD [11]. However, the greatest limitation is that these
studies differ in the GLS cut-off values, depending on the
vendors used and the populations studied. The cardiooncology expert consensus document of the American
Society of Echocardiography (ASE) and the European
Association for Cardiovascular Imaging (EACVI)
recommends the routine use of GLS in monitoring patients
during cancer therapy whenever possible. In patients with
available baseline strain measurements, a relative
percentage reduction in GLS of less than 8% is not
meaningful, whereas a change greater than 15% is likely to
indicate subclinical LV dysfunction (2,52). GLS
measurements based on 3 apical views is the preferred
technique for the detection of cardiotoxicity, according to
Thavendiranathan et al., even though single view LS is less
time consuming [53].
Longitudinal strain seems to be affected when
cardiotoxicity occurs. Bergamini et al. demonstrated that
2D GLS was the only parameter significantly modified
across the studies after 12 months, while, overall, 2D GCS
was not significantly reduced. Concerning the 2D GRS, the
analysis demonstrated a significant reduction of this
parameter, but not all the involved studies showed a
coherent result after the same follow-up period [54].
Given the established prognostic significance of the RV
dysfunction [55] for the outcome of the patients with heart
failure, the finding of concurrent RV impairment at the
time of diagnosis of LV cardiotoxicity makes RV GLS a
useful measurement during trastuzumab therapy. In the
recent study performed by Keramida et al., in patients
treated with trastuzumab, the RV FWLS (free wall
longitudinal strain) changes were modest. On the other
hand, the insignificant change of RV FWLS raises the
possibility that the detected impairment of RV GLS is
attributed mainly to the intraventricular septum that both
ventricles share. Also, the optimal cut-off value of the
relative percent change in the RV GLS to predict
cardiotoxicity was ≥14.8%, almost identical to the
established LV GLS cut-off. We should also point out that
both RV GLS and RV FWLS are size-independent
estimates of contraction, as opposed to peak S velocity and
TAPSE. But all the parameters proposed to detect early
changes in RV systolic function are load-dependent;

therefore, the presence of pulmonary hypertension may
affect them [56].
Data concerning bevacizumab-related cardiotoxicity
are scarce in the literature, but the same echocardiographic
markers as for trastuzumab are proposed in the follow-up
of patients, while the myocardial dysfunction induced
seems reversible [57].
To conclude, the most sensitive marker of the early
myocardial dysfunction in patients during and after the
chemotherapy treatment with either trastuzumab or
bevacizumab is global longitudinal strain GLS, having an
important prognostic value in the development of endstage HF [58].

Abbreviations
BNP - brain natriuretic peptide
ChT –chemotherapy
cTnC - troponin C
cTnI - troponin I
cTnT - troponin T
CTRCD - cancer therapy–related cardiac dysfunction
DTI - One-dimensional tissue Doppler
FWLS - free wall longitudinal strain
GCS - global circumferential strain
GLS - global longitudinal strain
GRS - global radial strain
HF - heart failure
hs-cTnI - high-sensitive troponin I
hs-cTnT - high-sensitive troponin T
LV - left ventricle
LVD - left ventricular dysfunction
LVEF - left ventricular ejection fraction
NT-proBNP - N-terminal pro-hormone brain
natriuretic peptide
RV - right ventricle
RVD - right ventricular dysfunction
us-cTnI - ultra-sensitive troponin I

Conclusions
To conclude, the most sensitive marker of the early
myocardial dysfunction in patients during and after the
chemotherapy treatment with either trastuzumab or
bevacizumab is global longitudinal strain GLS, having an
important prognostic value in the development of endstage HF [58].
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